Product Details
| Product Name: Benfotiamine | CAS No.: 22457-89-2 |
| Min. Order: 1kg | Purity: 99% |
| Supply Ability: g-kg-tons, free sample is available | Release date: 2026/07/09 |
| Lead time: In stock | Packaging: bottle/drum/bucket/IBC, as request. |
| Delivery: By sea, by air, by express | Origin: Manufacturer |
| Contact person: Jessica |
1. Product information
| Name | benfotiamine |
|---|---|
| Synonym | More Synonyms |
| Description | Benfotiamine is a synthetic S-acyl derivative of thiamine (vitamin B1); an antioxidant dietary supplement.IC50 value:Target: Benfotiamine, the lipid-soluble thiamine derivative used as a treatment for diabetic neuropathy, can inhibit three major pathways(the hexosamine pathway, the advanced glycation end product (AGE) formation pathway and the diacylglycerol (DAG)?protein kinase C (PKC) pathway）of hyperglycemic damage and prevent experimental diabetic retinopathy. Benfotiamine is a synthetic S-acyl derivative of thiamine (vitamin B1) for treating sciatica and other painful nerve conditions. More effective at increasing thiamin levels in blood and tissues than water-soluble salts like the previous vitamin B1. |
|---|---|
| Related Catalog | Signaling Pathways >> Others >> Others Natural Products >> Alkaloid Research Areas >> Neurological Disease |
| References | [1]. Tarallo S, Beltramo E, Berrone E, Porta M. Human pericyte-endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment. Acta Diabetol. 2012 Dec;49 Suppl 1:141-51. [2]. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway:Evidence from clinical studies. Diabetes Obes Metab. 2012 Dec 26. [3]. Hurt JK, Coleman JL, Fitzpatrick BJ, et al. Prostatic acid phosphatase is required for the antinociceptive effects of thiamine and benfotiamine. PLoS One. 2012;7(10):e48562. [4]. Hans-Peter Hammes, Xueliang Du, Diane Edelstein, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine, 2003, 9, 294 - 299 [5]. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. International Journal of Clinical Pharmacology and Therapeutics, 1996, 34(2):47-50 [6]. Benfotiamine |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 745.1±70.0 °C at 760 mmHg |
| Melting Point | 165oC |
| Molecular Formula | C19H23N4O6PS |
| Molecular Weight | 466.448 |
| Flash Point | 404.4±35.7 °C |
| Exact Mass | 466.107605 |
| PSA | 191.05000 |
| LogP | 1.81 |
| Vapour Pressure | 0.0±2.6 mmHg at 25°C |
| Index of Refraction | 1.645 |
| Storage condition | 2-8°C |
2. Packaging
For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.
For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product.
Or smaller package 1kg/bottle, 10kgs/bottle as request.
3. Shipping
4. Contact information
For more details, pls contact us freely.
Mob: 86 17630971917
WhatsApp/Skype/Wechat/LINE: 86 17630971917
Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-20 | ||
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-07-20 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-20 | ||
|
VIP7Y
|
Jinan Jianfeng Chemical Co., Ltd
|
2026-07-17 | ||
| $100.00 |
VIP4Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2026-07-06 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2025-12-24 | ||
|
Moxin Chemicals
|
2025-12-16 |
China